Pablo Loma-Osorio

Pablo Loma-Osorio

Auto-generated profile, based on publicly available information

Pablo Loma-Osorio

Servicio de Cardiología, Hospital Universitario Josep Trueta, Girona, Spain

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2022 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Closed access
PDF file
CTColoma Tiron
Coloma Tiron
Oscar CampuzanoOscar Campuzano
Oscar Campuzano
AFAnna Fernández-Falgueras
Anna Fernández-Falgueras
MAMireia Alcalde
Mireia Alcalde
PLPablo Loma-Osorio
Pablo Loma-Osorio
RBRamon Brugada
Ramon Brugada

1 February 2018 in Revista Espanola de Cardiologia
Verified
Journal Article
Closed access
PLPablo Loma-Osorio
Pablo Loma-Osorio
MNMaria Nuñez
Maria Nuñez
JAJaime Aboal
Jaime Aboal
DBDaniel Bosch
Daniel Bosch
PBPau Batlle
Pau Batlle
RBRamon Brugada
Ramon Brugada

4 March 2010 in International Journal of Cardiology
Verified
Journal Article
Open access
AGAna Garcia-Alvarez
Ana Garcia-Alvarez
MSMarta Sitges
Marta Sitges
XGXabier Garcia-Albeniz
Xabier Garcia-Albeniz
ASAlessandro Sionis
Alessandro Sionis
PLPablo Loma-Osorio
Pablo Loma-Osorio
JKJonathan M. Kalman
Jonathan M. Kalman
Hypereosinophilic syndrome (HES) is a rare disorder characterized by persistent marked eosinophilia combined with eosinophil-mediated organ damage. Myeloproliferative variants are associated with a high prevalence of cardiac involvement, which is very unusual in lymphocytic variants. Imatinib mesylate (Gleevec(R)) is a small molecule with tyrosine kinase activity that has shown marked effects in some individuals with HES. In this case report, we present a patient with a hypereosinophilic syndrome (lymphocytic variant) that first manifested as hypereosinophilia and heart failure secondary mainly to right ventricle systolic dysfunction. A week after imatinib therapy instauration the eosinophil count was within normal range but the patient suffered a severely left ventricular dysfunction that was restablished after early drug withdrawal. Surgical removal of a new onset mass in right atrium was required because of progressively growth despite anticoagulant therapy. Clinicians should be aware of the variable heart manifestations in patients with HES and the potential cardiotoxicity of imatinib.

1 August 2023 in Current Drug Safety
Verified
Journal Article
Open access
PDF file
KAKristopher Amaro-Hosey
Kristopher Amaro-Hosey
XCXavier Castells
Xavier Castells
LBLidia Blanco-Silvente
Lidia Blanco-Silvente
PLPablo Loma-Osorio
Pablo Loma-Osorio
DCDolors Capellà
Dolors Capellà
Background: The risk of sudden cardiac death (SCD) can be increased with the use of drugs. However, it has been described heterogeneously in the literature. Objective: This study aims to systematically review epidemiological studies dealing with druginduced sudden death, describe their methodologies, and summarize the results found. Methods: A scoping review has been carried out using Medline electronic database. The search was limited up to 2020. Epidemiological studies were included, and case reports or case series were excluded. Results: Out of 3,114 potential articles, 74 were included. Most studies originated from North America (40.5%) or Europe (39.2%). Case-control (47.3%) or cohort (40.5%) studies were the most common designs. The data for outcomes and exposure were retrieved mainly from administrative databases (37.8%) or medical charts/hospital discharge reports (32.4%), but most studies used several sources of information. A composite variable of sudden death or SCD, mainly with ventricular arrhythmia, was the most frequently used endpoint. Only 18.9% of the studies included autopsy results to confirm the death. Psychotropic drugs were the most frequently studied. An increased risk of different outcomes for typical antipsychotics, tricyclic antidepressants, domperidone, and antiepileptics is suggested. Conclusion: The methodologies used were highly heterogeneous, and the results were, in general, not conclusive. An improvement of the methodologies is needed to achieve a conclusion regarding the risk of SCD associated with drug use.

1 January 2010 in Revista Española de Cardiología (English Edition)
Verified
Journal Article
Closed access
XBXavier Bosch
Xavier Bosch
PLPablo Loma-Osorio
Pablo Loma-Osorio
EGEduard Guasch
Eduard Guasch
SNSantiago Nogué
Santiago Nogué
JPJosé Tomás Tomas Ortiz Pérez
José Tomás Tomas Ortiz Pérez
MSMiquel Sánchez
Miquel Sánchez

7 January 2011 in International Journal of Cardiology
Verified
Journal Article
Closed access
EGEduard Guasch
Eduard Guasch
ASAlessandro Sionis
Alessandro Sionis
JRJoan Carles Reverter
Joan Carles Reverter
RARut Andrea
Rut Andrea
PLPablo Loma-Osorio
Pablo Loma-Osorio
MHMagda Heras
Magda Heras